Researchers at Fred Hutchinson Cancer Center have developed a novel and validated quality of life instrument specifically designed for patients with acute myeloid leukemia (AML).
Developed through an iterative process involving feedback from patients, medical providers, and psychometricians, the AML-QOL underwent rigorous testing and validation, including factor analysis and test-retest reliability studies with 202 patients. The final instrument includes 27 items organized into 5 domains, a Symptom Index, and a Summary Score. The AML-QOL has been shown to have high internal consistency, good test-retest reliability, and strong convergent and divergent validity when compared to a non-disease-specific instrument. Furthermore, the Summary Score demonstrates good sensitivity to change when anchored to patient perception of QOL change, providing a clinically meaningful difference of 8-10 points out of 100. The AML-QOL is a reliable and valid measure of quality of life for patients with AML and other aggressive myeloid neoplasms.
To license this product, please complete, sign and return the license agreement to firstname.lastname@example.org. Further instructions are provided therein.
Please Note: Non-commercial use is free for academic and non-profit users. Fees for for-profit users are listed in the license agreements. In addition, some foreign language translations are available for use. Further information is provided in the license agreements.
When using the AML-QOL, please include “Copyright 2018 Fred Hutchinson Cancer Center. All Rights Reserved.” and credit/attribution in publications to Dr. Sarah Buckley, according to accepted publications standards.